TISSUE PROCUREMENT FACILITY SHARED RESOURCE The Tissue Procurement Facility (TPF) is the main conduit for access to protocol driven tissue-based research. As part of the 2019 strategic plan, this SR was expanded and reorganized to provide additional services and with a more robust pipeline for faculty conducting this type of clinical research. The expansion of this resource led to enhanced services including: ? More timely fresh tissue collection. TPF has developed a pipeline to collect fresh tissue for next-generation research focusing on single-cell and chip sequencing. The fresh tissue infrastructure requires significant collaboration between Surgical Pathology, Anatomic Pathology, TPF, and Clinical Protocol and Data Management (CPDM). For scRNA sequencing TPF has added an additional workflow to facilitate this methodology. ? Tissue dissociation. TPF is equipped for single-cell dissociation to process tissue to single-cell for investigators that do not have the technology to do so and/or are investigating more robust experiments. ? Ultrapure plasma processing. Ultra highspeed plasma purification for downstream cfDNA analysis. Ultrapure plasma will produce a significantly cleaner signal-to-noise ratio for investigators looking at cfDNA. TPFis led by an experienced faculty and staff. Dr. Calhoun is Director of Surgical Pathology and Anatomical Pathology at UNC and serves as Pathology Director. He works closely with the surgical liaison, co-leader HJ Kim to ensure responsible policies are in place for the procurement of research specimens following guidelines established by the UNC Hospitals. Amy Garratt serves as the Facility Director for the SR and its translational consenting and collection component. This is a well-managed resource with an operating budget of $1.0M. TPF requests $229,718 (21% of the total) for fiscal year 2020. LCCC members were more than 66% of the users in fiscal year 2019, virtually all other users were performing cancer research. The Facility procured, and distributed 46,091 specimens to support 154 different investigator-initiated studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089838
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Hamad, Ahmad; Iweala, Onyinye I; Henderson, Cory et al. (2018) Recurrent anaphylaxis during cardiac catheterization due to ethylene oxide. J Allergy Clin Immunol Pract 6:2148-2150
Mayer, Deborah K; Landucci, Gina; Awoyinka, Lola et al. (2018) SurvivorCHESS to increase physical activity in colon cancer survivors: can we get them moving? J Cancer Surviv 12:82-94
Huo, Dezheng; Perou, Charles M; Olopade, Olufunmilayo I (2018) Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply. JAMA Oncol 4:883-884
Howe, Chanelle J; Robinson, Whitney R (2018) Survival-related Selection Bias in Studies of Racial Health Disparities: The Importance of the Target Population and Study Design. Epidemiology 29:521-524
Byrne, James D; Yeh, Jen Jen; DeSimone, Joseph M (2018) Use of iontophoresis for the treatment of cancer. J Control Release 284:144-151
Wilkin, Timothy J; Chen, Huichao; Cespedes, Michelle S et al. (2018) A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis 67:1339-1346
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Ubil, Eric; Caskey, Laura; Holtzhausen, Alisha et al. (2018) Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. J Clin Invest 128:2356-2369
Horne, Hisani N; Oh, Hannah; Sherman, Mark E et al. (2018) E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. Sci Rep 8:6574
Ho, G-T; Aird, R E; Liu, B et al. (2018) MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation. Mucosal Immunol 11:120-130

Showing the most recent 10 out of 1525 publications